WO1992008979A1 - Analyse immunologique chimioluminescente heterogene et amplifiee - Google Patents
Analyse immunologique chimioluminescente heterogene et amplifiee Download PDFInfo
- Publication number
- WO1992008979A1 WO1992008979A1 PCT/US1991/008360 US9108360W WO9208979A1 WO 1992008979 A1 WO1992008979 A1 WO 1992008979A1 US 9108360 W US9108360 W US 9108360W WO 9208979 A1 WO9208979 A1 WO 9208979A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analyte
- specific binding
- compound
- chemiluminescent
- mixture
- Prior art date
Links
- 238000003018 immunoassay Methods 0.000 title claims description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 239000000523 sample Substances 0.000 claims abstract description 34
- 238000003556 assay Methods 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000003623 enhancer Substances 0.000 claims abstract description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 15
- 230000003321 amplification Effects 0.000 claims abstract description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 4
- 230000009870 specific binding Effects 0.000 claims description 49
- 239000012491 analyte Substances 0.000 claims description 35
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 239000007790 solid phase Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- BDQRMEBGHYKVLA-UHFFFAOYSA-N acridine-1-sulfonamide Chemical class C1=CC=C2C=C3C(S(=O)(=O)N)=CC=CC3=NC2=C1 BDQRMEBGHYKVLA-UHFFFAOYSA-N 0.000 claims description 12
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 claims description 9
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 9
- 229960002685 biotin Drugs 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 6
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 40
- 239000000243 solution Substances 0.000 description 28
- 239000000463 material Substances 0.000 description 22
- 239000002245 particle Substances 0.000 description 18
- 239000012528 membrane Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 239000004816 latex Substances 0.000 description 11
- 229920000126 latex Polymers 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 239000004793 Polystyrene Substances 0.000 description 10
- 229920002223 polystyrene Polymers 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- -1 aryl dioxetane derivatives Chemical class 0.000 description 8
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 150000002978 peroxides Chemical class 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000001745 anti-biotin effect Effects 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 6
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 5
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical group C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical class C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000005415 bioluminescence Methods 0.000 description 3
- 230000029918 bioluminescence Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000011152 fibreglass Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MIAKOEWBCMPCQR-YBXAARCKSA-N (2s,3r,4s,5r,6r)-2-(4-aminophenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C1=CC(N)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MIAKOEWBCMPCQR-YBXAARCKSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 229920002433 Vinyl chloride-vinyl acetate copolymer Polymers 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229940125665 acridine carboxamide Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108010009043 arylesterase Proteins 0.000 description 1
- 102000028848 arylesterase Human genes 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- XBGNERSKEKDZDS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]acridine-4-carboxamide Chemical compound C1=CC=C2N=C3C(C(=O)NCCN(C)C)=CC=CC3=CC2=C1 XBGNERSKEKDZDS-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920005671 poly(vinyl chloride-propylene) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Definitions
- This invention relates generally to immunoassays utilizing chemiluminescent compounds, and more particularly, relates to heterogeneous chemiluminescent immunoassays wherein a chemiluminescent signal provided by an immobilized product of an immunochemical reaction is amplified, resulting in a more sensitive assay.
- Immunoassays which employ chemiluminescent labels as the signal generating compound are known.
- the application of chemiluminescence generation and detection for immunoassays has been reviewed by W. R. Seitz, "Immunoassay Labels Based on Chemiluminescence and Bioluminescence," Clinical Biochemistry 17:120-126 (1984).
- an apparatus and method for performing such assays are available from Ciba-Coming Diagnostics' Magic-LiteTM system, which employs a chemiluminescent label and magnetizable microparticles. Because the brown colored microparticles optically interfere with the chemiluminescent signal, a very low mass of these particles is used. This in turn leads to very slow reactions.
- an assay for thyroid stimulating hormone (TSH) is reported to have a three-hour incubation period.
- many manipulation steps are involved, making this assay configuration difficult to automate.
- the AMERLITETM system employs a device, separate from the luminometer, in which the label is triggered.
- a method for performing a chemiluminescent assay involving directly exciting and measuring a chemiluminescent signal emanating off an immune complex immobilized on or in a solid, porous element that is used as a separation means in a heterogenous immunoassay and an apparatus for performing this measurement are described in pending U. S. Patent Applications Serial No. 07/425,643 and 07/206,645 which enjoy common ownership and are incorporated herein by reference.
- U. S. Patent No. 4,927,769 describes a method of enhancing the chemiluminescent signal generated from acridinium-ester labelled conjugates by the addition of surfactants.
- U. S. Patent No. 4,959,182 describes a method for amplifying the chemiluminescent signal generated from alkaline phosphatase-catalyzed 1 ,2-dioxetanes by the addition of a surfactant and a fluorescent compound attached to it.
- the present invention overcomes the shortcomings of the known art by providing a chemiluminescent signal amplification method that uses the specificity embodied in the interaction of "specific binding pairs.”
- the desired reaction signal is amplified to a much greater extent than the background signal, which improves assay sensitivity.
- the present invention further offers a common specific amplifying agent that can be used in a variety of assays.
- This invention provides a method for determining the presence of an anaiyte in a test sample by specific amplification of a chemiluminescent signal generated from a heterogeneous immunoassay, which method comprises: (a) incubating a test sample containing an anaiyte with an analyte-specific specific binding pair member, to form a first mixture; (b) incubating the first mixture for a time and under conditions sufficient to form analyte/analyte specific binding member pair complexes; (c) contacting the analyte/analyte specific binding member pair complexes with a probe comprising an enhancer compound attached to an analyte-specific binding member, to form a second mixture; (d) incubating the second mixture for a
- the enhancer compound may be selected from the group consisting of a hapten, a fluorescent compound and di-nitrophenol.
- a preferred enhancer compound is biotin.
- the chemiluminescent signal generating compound may be selected from the group consisting of acridinium esters, acridinium sulfonamides, 1 ,2-dioxetanes and luminol.
- a preferred chemiluminescent signal generating compound is an acridinium sulfonamide.
- the analyte-specific binding pair member can be attached to a solid pair.
- a kit for performing an amplified chemiluminescent assay also is provided.
- chemiluminescent properties of acridinium compounds and their use in immunoassays has been described, lmmunochemical tracers with acridinium esters or acridinium sulfonamide labels can be triggered with an alkaline peroxide solution to produce a chemiluminescent signal that maximizes after approximately two seconds. Light emission is completely extinguished after approximately ten (10) seconds.
- Acridinium sulfonamide labeling chemistry may be employed according to the invention for making a stable tracer of high quantum yield. This method is as described in pending
- EP 0 254051 (cited ⁇ uj_ a) describes a siloxy-substituted dioxetane as 4-(6-tert-bi ⁇ tlydimethyisiloxy-2- naphthyl)-4-methoxyspiro[1 ,2-dioxetane-3,2'adamantane] that is triggered with tetrabutlyammonium chloride solution to produce a chemiluminescent
- WO 881 00694 (WO 8906650, cited supra, describes long-lived emissions from alkaline phosphatase catalyzed reactions of 3-(2'- spiroadamantane)-4-methoxy-4-(3"-phosphoryloxy)-phenyl-1 ,2-dioxetanes (AMPPD) and of a similar ⁇ -galactosidase substrate. Also described is the use of these compounds in an immunoassay. Thus, alkaline phosphatase 1 0 labeling techniques are known and catalyzed dioxetane chemiluminescence may be used to generate long-lived signals.
- AMPPD 3-(2'- spiroadamantane)-4-methoxy-4-(3"-phosphoryloxy)-phenyl-1 ,2-dioxetanes
- a "specific binding member,” as used herein, is a
- specific binding pairs can include members that are analogs of the original specific binding members, for example, an analyte-analog.
- immunoreactive specific binding members include antigens, antigen
- hapten refers to a partial antigen or non-protein binding member which is capable of binding to an antibody, but which is not capable of eliciting antibody formation unless
- anaiyte is the substance to be detected which may be present in the test sample.
- the anaiyte can be any substance for which there exists a naturally occurring specific binding member (such as, an 35 antibody), or for which a specific binding member can be prepared.
- an anaiyte is a substance that can bind to one or more specific binding members in an assay.
- “Anaiyte” also includes any antigenic substances, haptens, antibodies, and combinations thereof. As a member of a specific
- the anaiyte can be detected by means of naturally occurring specific binding partners (pairs) such as the use of intrinsic factor protein as a member of a specific binding pair for the determination of Vitamin B12, or the use of iectin as a member of a specific binding pair for the determination of a carbohydrate.
- the anaiyte can include a protein, a peptide, an amino acid, a hormone, a steroid, a vitamin, a drug including those administered for therapeutic purposes as well as those administered for illicit purposes, a bacterium, a virus, and metabolites of or antibodies to any of the above substances.
- the details for the preparation of such antibodies and the suitability for use as specific binding members are well known to those skilled in the art.
- a “capture reagent”, as used herein, refers to an unlabeled specific binding member which is specific either for the anaiyte as in a sandwich assay, for the indicator reagent or anaiyte as in a competitive assay, or for an ancillary specific binding member, which itself is specific for the anaiyte, as in an indirect assay.
- the capture reagent can be directly or indirectly bound to a solid phase material before the performance of the assay or during the performance of the assay, thereby enabling the separation of immobilized complexes from the test sample .
- test sample can be a sample of biological fluid, such as whole blood or whole blood components including red blood ceils, white blood cells, platelets, serum and plasma; ascites; urine; cerebrospinal fluid; and other constituents of the body which may contain the anaiyte of interest.
- biological fluid such as whole blood or whole blood components including red blood ceils, white blood cells, platelets, serum and plasma; ascites; urine; cerebrospinal fluid; and other constituents of the body which may contain the anaiyte of interest.
- test samples may be obtained from water, soil and vegetation.
- probe means a member of the specific binding pair attached to an "enhancer compound".
- An "enhancer compound” can be any compound used in the assay which can enhance the signal generated by the chemiluminescent compound.
- enhancer compounds include haptens such as biotin, and also include fluorescein, di- nitrophenol, and the like.
- chemiluminescent compound is meant to include all compounds capable of generating a chemiluminescent signal such as acridinium esters, acridinium sulfonamides, 1 ,2-dioxetanes, luminol, or enzymes that catalyze chemiluminescent substrates, and the like.
- Conjugate means a chemiluminescent compound to which a compound specific for the enhancer compound (a specific binding member of the enhancer) is attached.
- a compound specific for the enhancer compound a specific binding member of the enhancer
- the enhancer compound utilized is biotin, then anti-biotin, or avidin, can be used as the enhancer-specific compound.
- a solid phase may be used according to the method of the invention.
- a "solid phase”, as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction.
- the solid phase can be chosen for its intrinsic ability to attract and immobilize the capture reagent.
- the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent.
- the additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent.
- the receptor molecule can be any specific binding member which is immobilized upon the solid phase and which has the ability to immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid phase material before the performance of the assay or during the performance of the assay.
- An assay device for the present invention can have many configurations, several of which are dependent upon the material chosen as the solid phase.
- the solid phase can include any suitable porous material.
- porous is meant that the material is one through which the test sample can easily pass and includes both bibulous and non- bibulous solid phase materials.
- the solid phase can include a fiberglass, cellulose, or nylon pad for use in a pour and flow- through assay device having one or more layers containing one or more of the assay reagents; a dipstick for a dip and read assay; a test strip for wicking (e.g., paper) or thin layer chromatographic or capillary action (e.g., nitrocellulose) techniques; or other porous or open pore materials well known to those skilled in the art (e.g., polyethylene sheet material).
- the solid phase is not limited to porous materials.
- the solid phase can also comprise polymeric or glass beads, microparticles, tubes, sheets, plates, slides, wells, tapes, test tubes, or the like, or any other material which has an intrinsic charge or which can retain a charged substance.
- Natural, synthetic, or naturally occurring materials that are synthetically modified, can be used as a solid phase including polysaccharides, e.g., cellulose materials such as paper and cellulose derivatives such as cellulose acetate and nitrocellulose; silica; inorganic materials such as deactivated alumina, diatomaceous earth, MgSO-4, or other inorganic finely divided material uniformly dispersed in a porous polymer matrix, with polymers such as vinyl chloride, vinyl chloride- propylene copolymer, and vinyl chloride-vinyl acetate copolymer; cloth, both naturally occurring (e.g., cotton) and synthetic (e.g., nylon); porous gels such as silica gel, agarose, dextran, and gelatin; polymeric films such as poiyacrilamide; and the like.
- the solid phase should have reasonable strength or strength can be provided by means of a support, and it should not interfere with the production of a detectable signal.
- Preferred solid phase materials for flow-through assay devices include filter paper such as a porous fiberglass material or other fiber matrix materials.
- the thickness of such material is not critical, and will be a matter of choice, largely based upon the properties of the sample or anaiyte being assayed, such as the fluidity of the test sample.
- a charged substance can be coated directly to the material or onto microparticles which are then retained by a solid phase support material.
- microparticles can serve as the solid phase, by being retained in a column or being suspended in the mixture of soluble reagents and test sample, or the particles themselves can be retained and immobilized by a solid phase support material.
- retained and immobilized is meant that the particles on or in the support material are not capable of substantial movement to positions elsewhere within the support material.
- the particles can be selected by one skilled in the art from any suitable type of paniculate material and include those composed of polystyrene, polymethylacrylate, polypropylene, latex, polytetrafluoroethylene, polyacrylonitrile, polycarbonate, or similar materials.
- the size of the particles is not critical, although it is preferred that the average diameter of the particles be smaller than the average pore size of the support material being used.
- a test sample which may contain an anaiyte to be detected is contacted with a solid phase to which a binding pair member specific for the anaiyte is attached, to form a mixture.
- This mixture is incubated for a time and under conditions sufficient for analyte/analyte specific binding pair member complexes to form.
- these complexes are contacted with a probe comprising an enhancer compound attached to an analyte-specific binding par member and incubated again, to form a second mixture.
- This second mixture is incubated for a time and under conditions sufficient for analyte/analyte specific binding pair member/probe complexes to form.
- the analyte/analyte specific binding pair member/probe complexes then are contacted with a conjugate comprising a chemiluminescent signal generating compound conjugated to an enhancer compound binding member, to form a third mixture.
- This third mixture is incubated for a time and under conditions sufficient to form analyte/analyte specific binding pair member/probe/conjugate complexes.
- the presence of the anaiyte in the test sample is determined by measuring the signal generated by the chemiluminescent compound.
- a sandwich assay can be performed wherein a soluble capture reagent can include an analyte-specific binding member which has been bound to a charged substance such as an anionic substance.
- the present invention also can be used to conduct a competitive assay.
- the soluble capture reagent again includes a specific binding member which has been attached to a charged substance, such as an anionic polymer, with which to bind a specific binding partner.
- Carboxylated polystyrene latex particles were purified by stirring with an equal w/w amount of a mixed-bed ion-exchange resin for three (3) hours at ambient room temperature. The particles were isolated and then diluted to a 0.5% solids concentration in 0.02M MES (pH 6.0) and to the suspension then was added 1-ethyl-3-(3-dimethylaminopropy)-carbodiimide in a w/w ratio of 3:1 (EDAC:latex). This mixture was allowed to stir for 20 minutes at ambient room temperature before purified HTLV-I antigen lysate was added in an amount to achieve a final concentration of 60 ⁇ g/ml.
- the suspension then was stirred overnight at ambient room temperature before the coated particles were isolated by centrifugation and purified by three cycles of resuspension-centrifugation in a pH 7.2 solution of 0.01 M phosphate and 0.15 M NaCI, containing 0.1% Tween-20®. After the final centrifugation step, the solids were diluted to a concentration of 0.1% solids in the buffer .
- Viral and recombinant viral proteins were labelled with fluoresceinisothiocyanate using the procedure of Samuel et al., J. Immunol. Methods 107:217-224 (1988).
- the antibody was dialyzed against 0.1 M phosphate (pH 8.0), containing 0.15 M NaCI, and the protein then was adjusted to a concentration of 1 mg/ml in the same buffer.
- the activated acridinium derivative at a 5 to 10 molar excess then was added to the antibody solution at room temperature.
- the reaction mixture was centrifuged (12,000 ⁇ m for two (2) minutes) to remove aggregates, and the supernatant solution then was applied to a TSK-250 gel filtration column, which previously had been equilibrated with 0.01 M sodium phosphate, pH 6.3, containing 0.15 M NaCI.
- One ml fractions were collected, and the absorbance monitored at 280 nm and 369 nm.
- Example 2 previously coated with HTLV-I antigen as described in Example 1 in a pH 7.5 solution of 10% sucrose (w/w%), 0.1% Bovine Serum Albumin (BSA), 0.1% Tween-20®, 0.1 M phosphate and 0.1% sodium azide was added to 100 ⁇ l of sample in a reaction well. The suspension was then allowed to incubate for about 20 minutes at 40°C before being transferred to the capture membrane by two successive 300 ⁇ l washes of pH 7.2, 0.01 M phosphate, 0.15 M NaCI, containing 0.1% sodium azide.
- BSA Bovine Serum Albumin
- the washed capture membrane then was treated with 30 ⁇ l of a 167 ng/ml solution of anti-biotin to which a chemiluminescent acridinium sulfonamide moiety had been attached (as in Example 4), in 0.01 M MES (pH 6.3), 0.15 M NaCI, 2% BSA, and 0.5% Triton® containing 0.1% sodium azide. After a further ten (10) minute incubation at 40°C, the capture membrane was washed with three (3) 100 ⁇ l portions of a pH 5.5 solution of 0.1 M MES and 0.15 M NaCI containing 0.1% sodium azide.
- the washed capture membrane then was incubated for ten (10) minutes at 40°C prior to being treated with an alkaline peroxide solution (0.25 N NaOH containing 0.3% peroxide). The chemiluminescence was read for six (6) seconds and the presence or absence of anti-HTLV-l was determined.
- HCV antigen 20 ⁇ g HCV antigen was mixed with 100 mg of 2.66 micron diameter polystyrene latex particles in 20 ml of a pH 7.0, 0.1 M phosphate buffer and allowed to stir overnight at room temperature. The solids then were isolated by centrifugation (17,000 m for 25 minutes) and then purified by three cycles of resuspension-centrifugation in 20 ml of a pH 7.0, 0.1 M phosphate buffer containing 0.005% Tween-20®.
- biotinamidocaproate N-hydroxysuccinamide ester was added to 500 ⁇ g of HCV antigen in 2.5 ml of 0.05 pH 8.5 borate, containing 0.1 % Tween-20®. After stirring at room temperature for two (2) hours, 50 mg of BSA was added, and the solution was dialyzed ovemight at ambient room temperature against two- 500 ml changes of 0.02 M Tris buffer (pH 8.5) containing 0.002 M dithiothreitol and 0.1% Tween-20®.
- the washed suspension then was allowed to incubate for about ten (10) minutes at 40°C before it was treated with 30 ⁇ l of 660 ng/ml solution of biotinylated recombinant HCV antigen (prepared as in Example 7) in 0.02 M borate (pH 8.5), 5% BSA, and 5.0% Triton X-100® containing 0.1% sodium azide.
- the capture membrane then was allowed to incubate for 20 minutes before it was washed with three (3) 100 ⁇ l portions of a pH 8.0 wash solution which comprised 0.1 M borate, 0.15 M NaCI, and 0.05% lithium dodecylsulfate (LDS) containing 0.1% sodium azide.
- a pH 8.0 wash solution which comprised 0.1 M borate, 0.15 M NaCI, and 0.05% lithium dodecylsulfate (LDS) containing 0.1% sodium azide.
- the washed capture membrane then was treated with 30 ⁇ l of a 165 ng/ml solution of anti-biotin in 0.01 M phosphate (pH 6.3), 0.15 M NaCI, 5% calf serum, and 0.1% Triton® containing 0.1% sodium azide, to which a chemiluminescent acridinium sulfonamide moiety had been attached (prepared as in Example 4).
- the capture membrane was washed with three (3) 100 ⁇ l portions of a pH 8.5 solution of 0.1 M borate, 0.15 M NaCI and 0.02% SDS, containing 0.1% sodium azide.
- the washed capture membrane then was incubated for ten (10) minutes at 40°C prior to being treated with an alkaline peroxide solution (0.25 N NaOH containing 0.3% peroxide). The chemiluminescence was read for six (6) seconds and the presence or absence of anti-HCV was determined.
- HIV antigen (10 mg) in 34.28 ml of 0.5 M borate buffer (pH 8.5) is mixed with 10 ml of a 0.5% solids suspension of polystyrene latex particles, and then 55.72 ml of deionized water was added. The suspension was then allowed to stir overnight at room temperature. The solids were then isolated by centrifugation (17,000 ⁇ m for 30 minutes) and then purified by three cycles of resuspension-centrifugation in 0.1 M phosphate buffer (pH 7.0) containing 0.1% Tween®. The coated particles were then resuspended, allowed to stir gently at 56°C for one (1 ) day, and then stored at room temperature prior to use.
- HIV antigen (1.9 mg) in 2.278 ml of 0.1 M borate buffer (pH 8.5), containing 250 mm NaCI and 0.1% sodium azide, was treated with 0.125 ml of 10% Triton® for 30 minutes. Then, 97 ⁇ l of 5 mg/ml of biotinamidocaproate N-hydroxysuccinamide ester dissolved in DMF, was added. The reaction mixture was allowed to stir at room temperature for about two (2) hours. The mixture was dialyzed extensively against 0.1 M borate buffer (pH 8.5) containing 250 mm NaCI, 0.1% SDS, and 0.1% sodium azide.
- the capture membrane then was allowed to incubate for 20 minutes before it was washed with three (3) 100 ⁇ l portions of a pH 8.5 wash solution which comprised 0.1 M borate, 0.15 M NaCI, and 0.03% LDS containing 0.1% sodium azide.
- the washed capture membrane then was treated with 30 ⁇ l of a 167 ng/ml solution of anti-biotin antibody to which a chemiluminescent acridinium sulfonamide moiety had been attached (prepared as in Example 4) in 0.01 M phosphate (pH 6.3), 0.15 M NaCI, 5% BSA, and 1.0 % Triton® containing 0.1% sodium azide.
- the capture membrane was washed with five (3) 100 ⁇ l portions of a pH 8.5 solution of 0.1 M borate, 0.15 M NaCI and 0.01% LDS, containing 0.1% sodium azide. The washed capture membrane then was incubated for ten (10) minutes at 40°C prior to being treated with an alkaline peroxide solution (0.25 N NaOH containing 0.3% peroxide). The chemiluminescence was read for six (6) seconds and the presence or absence of anti-HIV was determined.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU91049/91A AU650503B2 (en) | 1990-11-09 | 1991-11-08 | Amplified heterogeneous chemiluminescent immunoassay |
JP4501517A JPH06501559A (ja) | 1990-11-09 | 1991-11-08 | 増幅不均一化学ルミネッセンスイムノアッセイ |
KR1019930701366A KR930702680A (ko) | 1990-11-09 | 1991-11-08 | 증폭된 불균질 화학발광 면역 검정법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61123590A | 1990-11-09 | 1990-11-09 | |
US611,235 | 1990-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992008979A1 true WO1992008979A1 (fr) | 1992-05-29 |
Family
ID=24448191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/008360 WO1992008979A1 (fr) | 1990-11-09 | 1991-11-08 | Analyse immunologique chimioluminescente heterogene et amplifiee |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0556331A4 (fr) |
JP (1) | JPH06501559A (fr) |
KR (1) | KR930702680A (fr) |
AU (1) | AU650503B2 (fr) |
CA (1) | CA2095825A1 (fr) |
TW (1) | TW205095B (fr) |
WO (1) | WO1992008979A1 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996002839A1 (fr) * | 1994-07-15 | 1996-02-01 | Abbott Laboratories | Amplification de signal chimioluminescent |
WO1996032004A3 (fr) * | 1995-04-14 | 1996-11-14 | Abbott Lab | Essai immunologique par chimiluminescence pour la detection d'anticorps |
US5858665A (en) * | 1996-07-25 | 1999-01-12 | Navix, Inc. | Homogeneous diagnostic assay method utilizing simultaneous target and signal amplification |
WO1999015898A1 (fr) * | 1997-09-22 | 1999-04-01 | Chiron Corporation | Procede pour detecter des anticorps dans un echantillon |
WO2000014544A1 (fr) * | 1998-09-03 | 2000-03-16 | Abbott Laboratories | Procede de dosage immunologique chimioluminescent servant a detecter des anticorps contre differents virus |
US6261764B1 (en) | 1997-09-22 | 2001-07-17 | Chiron Corporation | Buffers for stabilizing antigens |
EP1412538A4 (fr) * | 2001-06-26 | 2005-04-06 | Abbott Lab | Procedes servant a detecter simultanement des antigenes de hcv et des anticorps anti-hcv |
EP2397566A1 (fr) * | 2001-06-26 | 2011-12-21 | Abbott Laboratories | Procédés pour la détection simultanée d'antigènes HCV et d'anticorps HCV |
EP2699906A4 (fr) * | 2011-04-20 | 2015-04-29 | Access Medical Systems Ltd | Amplification cyclique de polymère luminescent |
CN111781345A (zh) * | 2020-06-30 | 2020-10-16 | 上海透景生命科技股份有限公司 | 化学发光标记物标记抗原稳定剂及其应用 |
US11437141B2 (en) | 2009-04-30 | 2022-09-06 | Dexcom, Inc. | Performance reports associated with continuous sensor data from multiple analysis time periods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4927769A (en) * | 1987-07-08 | 1990-05-22 | Ciba Corning Diagnostics Corp. | Method for enhancement of chemiluminescence |
US4935339A (en) * | 1985-05-07 | 1990-06-19 | Nichols Institute Diagnostics | Delayed solid phase immunologic assay |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228237A (en) * | 1978-09-21 | 1980-10-14 | Calbiochem-Behring Corp. | Methods for the detection and determination of ligands |
FR2523311B1 (fr) * | 1982-03-12 | 1985-12-27 | Pasteur Institut | Produit de couplage entre une albumine et un ligand specifique, obtention et applications dans le domaine biologique |
NZ211888A (en) * | 1984-05-10 | 1987-08-31 | Abbott Lab | Biotin-antibiotin immunoassay for detecting ligands |
-
1991
- 1991-11-08 JP JP4501517A patent/JPH06501559A/ja active Pending
- 1991-11-08 WO PCT/US1991/008360 patent/WO1992008979A1/fr not_active Application Discontinuation
- 1991-11-08 KR KR1019930701366A patent/KR930702680A/ko not_active Withdrawn
- 1991-11-08 CA CA002095825A patent/CA2095825A1/fr not_active Abandoned
- 1991-11-08 AU AU91049/91A patent/AU650503B2/en not_active Ceased
- 1991-11-08 EP EP19920901340 patent/EP0556331A4/fr not_active Withdrawn
- 1991-11-22 TW TW080109188A patent/TW205095B/zh active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935339A (en) * | 1985-05-07 | 1990-06-19 | Nichols Institute Diagnostics | Delayed solid phase immunologic assay |
US4927769A (en) * | 1987-07-08 | 1990-05-22 | Ciba Corning Diagnostics Corp. | Method for enhancement of chemiluminescence |
Non-Patent Citations (3)
Title |
---|
Clinc. Chem. Vol. 29. No. 8. issued August 1983, WEEKS et al. "Acridinium Esters as High-Specific Activity Labels in Immunoassay", pages 147-1479, see entire document. * |
Journal of Immun. Methods, Vol. 101, No. 1, issued 16 July 1987, HART. "The use of acridinium ester-labelled streptowidin in immunoassays", pages 91-96, see entire document. * |
See also references of EP0556331A4 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996002839A1 (fr) * | 1994-07-15 | 1996-02-01 | Abbott Laboratories | Amplification de signal chimioluminescent |
WO1996032004A3 (fr) * | 1995-04-14 | 1996-11-14 | Abbott Lab | Essai immunologique par chimiluminescence pour la detection d'anticorps |
US5705330A (en) * | 1995-04-14 | 1998-01-06 | Abbott Laboratories | Chemiluminescent immunoassay for antibody detection |
US6114117A (en) * | 1996-07-25 | 2000-09-05 | Medical Analysis Systems, Inc. | Homogeneous diagnostic assay method utilizing simultaneous target and signal amplification |
US5858665A (en) * | 1996-07-25 | 1999-01-12 | Navix, Inc. | Homogeneous diagnostic assay method utilizing simultaneous target and signal amplification |
US6261764B1 (en) | 1997-09-22 | 2001-07-17 | Chiron Corporation | Buffers for stabilizing antigens |
WO1999015898A1 (fr) * | 1997-09-22 | 1999-04-01 | Chiron Corporation | Procede pour detecter des anticorps dans un echantillon |
US6391540B1 (en) | 1997-09-22 | 2002-05-21 | Chiron Corporation | Method for detecting antibodies in a sample |
US6537745B2 (en) | 1997-09-22 | 2003-03-25 | Chiron Corporation | Buffers for stabilizing antigens |
WO2000014544A1 (fr) * | 1998-09-03 | 2000-03-16 | Abbott Laboratories | Procede de dosage immunologique chimioluminescent servant a detecter des anticorps contre differents virus |
US6203974B1 (en) | 1998-09-03 | 2001-03-20 | Abbott Laboratories | Chemiluminescent immunoassay for detection of antibodies to various viruses |
EP1412538A4 (fr) * | 2001-06-26 | 2005-04-06 | Abbott Lab | Procedes servant a detecter simultanement des antigenes de hcv et des anticorps anti-hcv |
EP2397566A1 (fr) * | 2001-06-26 | 2011-12-21 | Abbott Laboratories | Procédés pour la détection simultanée d'antigènes HCV et d'anticorps HCV |
US11437141B2 (en) | 2009-04-30 | 2022-09-06 | Dexcom, Inc. | Performance reports associated with continuous sensor data from multiple analysis time periods |
EP2699906A4 (fr) * | 2011-04-20 | 2015-04-29 | Access Medical Systems Ltd | Amplification cyclique de polymère luminescent |
US9435794B2 (en) | 2011-04-20 | 2016-09-06 | Access Medical Systems, Ltd. | Luminescent polymer cyclic amplification |
US10718764B2 (en) | 2011-04-20 | 2020-07-21 | Access Medical Systems, Ltd. | Electrochemiluminescent detection system |
CN111781345A (zh) * | 2020-06-30 | 2020-10-16 | 上海透景生命科技股份有限公司 | 化学发光标记物标记抗原稳定剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
KR930702680A (ko) | 1993-09-09 |
EP0556331A1 (fr) | 1993-08-25 |
EP0556331A4 (fr) | 1994-10-12 |
AU650503B2 (en) | 1994-06-23 |
JPH06501559A (ja) | 1994-02-17 |
AU9104991A (en) | 1992-06-11 |
TW205095B (fr) | 1993-05-01 |
CA2095825A1 (fr) | 1992-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2217818C (fr) | Essai immunologique par chimiluminescence pour la detection d'anticorps | |
AU609241B2 (en) | Ion-capture assays and devices | |
Self et al. | Advances in immunoassay technology | |
JP2001505663A (ja) | 抗原特異的IgG検出 | |
WO2002090961A2 (fr) | Systemes et procedes de detection d'analytes dans des liquides biologiques | |
AU650503B2 (en) | Amplified heterogeneous chemiluminescent immunoassay | |
US6258551B1 (en) | Method for carrying out an immunoassay in a multiphase system | |
WO1992012255A1 (fr) | Determination simultanee d'analytes multiples a l'aide d'une technique de chimioluminescence heterogene a resolution temporelle | |
US5143825A (en) | Stabilized substrate for use in an immunoassay | |
CA2064972A1 (fr) | Essai immunologique pour immunoglobulines | |
JPH06508689A (ja) | 特異的リガンドを検出するための検定 | |
IE60253B1 (en) | "Membrane affinity concentration immunoassay" | |
JP3502497B2 (ja) | 複合化被検物質誘導体を用いた競合イムノアッセイ | |
JP2001511820A (ja) | サイクロスポリン誘導体およびその使用 | |
CA1234044A (fr) | Reactif d'analyse a liaison biospecifique | |
EP0338045A4 (en) | Solid-phase non-separation enzyme assay | |
AU601674B2 (en) | A method for determining a ligand | |
JPH08220095A (ja) | 沈殿可能な固相を用いる不均一系イムノアッセイ | |
Ngo | Enzyme mediated immunoassay: an overview | |
CA1335174C (fr) | Test enzymatique en phase solide en faisant pas appel a une separation | |
WO2001044499A9 (fr) | Composants du complement marque modifie pour immunodosages | |
Ferenčík et al. | Immunochemical methods | |
JP2002196000A (ja) | 類縁体に起因する非特異反応を抑制した新規測定法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992901340 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2095825 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1992901340 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992901340 Country of ref document: EP |